Home Newsfeeds Stephens & Co. Reiterates Equal-Weight on Itron, Maintains $45 Price Target

Stephens & Co. Reiterates Equal-Weight on Itron, Maintains $45 Price Target

Stephens & Co. analyst Tommy Moll reiterates Itron (NASDAQ:ITRI) with a Equal-Weight and maintains $45 price target.

byBenzinga Newsdesk

February 28, 2023

1 minute read

Stephens & Co. analyst Tommy Moll reiterates Itron (NASDAQ:ITRI) with a Equal-Weight and maintains $45 price target.

Key Nvidia, Apple Supplier TSMC-Led AI Stock Craze Boosts Taiwan’s ETF Market With $50B Surge

By Benzinga Neuro

April 10, 8:19 AM

Retail investors, who make up about 80% of equity fund assets in Taiwan, are increasingly pouring their savings into ETFs.

TSM

Palisade Bio Presents Development Overview Of PALI-2108 At The IBD Innovate: Product Development For Crohn’s & Colitis April 9-10, 2024 In Cambridge, MA

By Benzinga Newsdesk

April 10, 8:16 AM

– PALI-2108 in development for the treatment of moderate-to-severe ulcerative colitis (UC) advancing towards Phase 1 clinical study before year endCarlsbad, CA, April 10, 2024 (GLOBE NEWSWIRE) -- Palisade Bio,

PALI

BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity Of Bria-OTS+ And Bria-PROS+ Clinical Candidates For Breast And Prostate Cancer

By Benzinga Newsdesk

April 10, 8:10 AM

Preclinical data shows that BriaCell's Bria-OTS+™ and Bria-PROS+™ effectively induce an anti-cancer immune response via multiple mechanisms including naïve helper and killer T cells, dendritic cells, and

BCTX